Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Liver Int ; 34(8): 1241-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24939565

ABSTRACT

BACKGROUND & AIMS: The Alaska Native population is one of few populations in the world with a high prevalence of autoimmune hepatitis. The objective of this study was to determine the frequency and HLA and clinical associations of autoantibodies in Alaska Native people with autoimmune hepatitis. METHODS: Alaska Native individuals with autoimmune hepatitis were recruited in clinics conducted statewide. Sera were tested for the presence of autoantibodies described in either autoimmune hepatitis or rheumatic disease. Associations between autoantibodies and HLA alleles and clinical features were assessed. RESULTS: Seventy-one patients were included. At the study visit, 34 patients (47.9%) had antibodies to double-stranded DNA by immunofluorescence; 27 (38.0%) had anti-neutrophil cytoplasmic antibodies; and 11 (15.5%) had anti-Ro antibodies. Only one person had antibodies against soluble liver antigen, and in that person, anti-Ro was absent. Associations were found between autoantibodies and HLA alleles, including positive associations between HLA DR3 and anti-double-stranded DNA antibodies and between HLA DR14 and antineutrophil cytoplasmic antibodies. There was no association between autoantibodies and clinical outcomes. CONCLUSIONS: As in other populations, the prevalence of anti-double-stranded DNA antibodies and antineutrophil cytoplasmic antibodies is high in Alaska Native people with autoimmune hepatitis. In contrast to data from other populations, there is a lower prevalence of anti-soluble liver antigen and a lack of association between anti-Ro and anti-soluble liver antigen. In addition, the HLA profile and associations with autoantibodies are unique. No clear prognostic implications of autoantibodies have emerged in this population.


Subject(s)
Autoantibodies/blood , Hepatitis, Autoimmune/epidemiology , Hepatitis, Autoimmune/immunology , Alaska/epidemiology , Antibodies, Antineutrophil Cytoplasmic/blood , Antibodies, Antinuclear/blood , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , HLA-DR3 Antigen/blood , Humans , Indians, North American , Prevalence
2.
Can J Gastroenterol ; 25(1): 21-7, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21258664

ABSTRACT

BACKGROUND: In autoimmune hepatitis (AIH) patients treated with azathioprine, the utility of measuring thiopurine methyltransferase (TPMT) and azathioprine metabolites has been limited. OBJECTIVE: To evaluate the association between TPMT genotype and enzyme activity, and the impact of TPMT enzyme activity on levels of azathioprine metabolites and leukopenia to assess the clinical utility of monitoring azathioprine metabolites in Alaska Native and other non-Caucasian AIH patients. METHODS: Individuals with AIH were recruited at the Alaska Native Medical Center (Alaska, USA) and the University of Texas Southwestern Medical Center (Texas, USA). Identification of TPMT genotype and measurement of enzyme activity were performed. The metabolites 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMP) were measured in participants who were on azathioprine, and the associations with disease remission and leukopenia were assessed. RESULTS: Seventy-one patients with AIH were included. The distribution of TPMT genotypes was similar to that reported in other populationbased studies. TPMT genotype and phenotype were strongly associated (P<0.0001). Levels of 6-TGN and 6-MMP correlated with azathioprine dose only in individuals with normal TPMT enzyme activity. Patients with leukopenia due to azathioprine were no more likely to have abnormal TPMT enzyme levels than those without leukopenia (P=1.0). No specific level of 6-TGN metabolites was associated with remission or leukopenia. DISCUSSION: Results of the present study were consistent with previous studies in Caucasian populations. TPMT genotype and phenotype correlated well, and levels of 6-TGN and 6-MMP metabolites were not associated with remission of AIH or toxicity of azathioprine. CONCLUSIONS: The present study confirmed the limited utility of monitoring levels of azathioprine metabolites in AIH patients.


Subject(s)
Azathioprine/metabolism , Hepatitis, Autoimmune/metabolism , Indians, North American , Methyltransferases/metabolism , Adult , Alaska , Biomarkers/blood , Female , Genetic Association Studies , Hepatitis, Autoimmune/drug therapy , Hepatitis, Autoimmune/genetics , Humans , Male , Mercaptopurine/metabolism , Methyltransferases/genetics , Middle Aged
3.
Liver Int ; 27(5): 627-32, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17498247

ABSTRACT

BACKGROUND: The highest incidence of hepatitis B virus (HBV)-associated vasculitis in the world has been reported in Alaska Natives. We examined the incidence of HBV-associated vasculitis before and after mass HBV vaccine immunization and the association between HBV genotype and vasculitis in a population-based cohort study in Alaska natives chronically infected with HBV. METHODS: Genotyping was performed in vasculitis cases and 644 hepatitis B-positive controls without vasculitis using polymerase chain reaction and sequencing of the S gene. Occurrence of HBV vasculitis from 1974 to 2004 was calculated. HBV vasculitis patients and controls were also tested for basal core promoter and precore mutations. RESULTS: Fifteen cases of HBV-associated vasculitis were identified: 13 (86%) had genotype D and one each genotype A and F. Genotype D was more commonly found in patients with vasculitis than controls [odd ratio (OR)=5.9, confidence interval (95% CI) 1.2, 21.8; P<0.015). CONCLUSIONS: HBV-associated vasculitis was associated with genotype D.


Subject(s)
DNA, Viral/blood , Hepatitis B virus/genetics , Hepatitis B/complications , Inuit , Vasculitis/etiology , Adolescent , Adult , Aged , Case-Control Studies , Child , Child, Preschool , Female , Genes, Viral , Genotype , Hepatitis B/ethnology , Hepatitis B/virology , Humans , Male , Middle Aged , Mutation , Treatment Outcome , Vasculitis/ethnology
4.
J Infect Dis ; 195(1): 5-11, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17152003

ABSTRACT

BACKGROUND: The development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection has been associated with specific HBV genotypes and the presence of specific mutations. METHODS: From a cohort of Alaska Native people with chronic HBV infection, we genotyped 47 patients with HCC and 1129 patients without HCC, and we tested patients with HCC and control patients for mutations in the basal core promoter and precore regions. RESULTS: Genotype F was found in 68% of patients with HCC, versus 18% of those without HCC (P<.001). For patients with genotype F, the median age at diagnosis of HCC was lower than that for patients with other genotypes (22.5 vs. 60 years, respectively; P=.002). Overall, there were no significant differences in the number of basal core promoter and precore region mutations between patients with HCC and control patients. CONCLUSIONS: We found a significant association between genotype F and the development of HCC among Alaska Native people with chronic HBV infection but no significant association between HCC and basal core promoter or precore mutations in genotype F.


Subject(s)
Carcinoma, Hepatocellular/virology , Hepatitis B virus/genetics , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/virology , Mutation/genetics , Promoter Regions, Genetic/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Alaska/epidemiology , Cohort Studies , Genotype , Hepatitis B virus/classification , Hepatitis B, Chronic/physiopathology , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Liver Cirrhosis/physiopathology , Liver Cirrhosis/virology
5.
Am J Gastroenterol ; 97(9): 2402-7, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12358264

ABSTRACT

OBJECTIVE: There is limited information on the prevalence of autoimmune liver disease in nonwhite populations. We conducted a population-based study on the prevalence of autoimmune liver diseases in Alaska natives. METHODS: Clinical records from 1984 to July, 2000 were reviewed to identify Alaska natives with autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis, autoimmune cholangitis, and overlap syndromes of two of the above. AIH was defined as definite or probable, based on criteria established by the International Autoimmune Hepatitis Group. The diagnosis of PBC was based on a positive antimitochondrial antibody of > or = 1: 40, biochemical evidence of cholestasis, and compatible liver biopsy. Autoimmune cholangitis was defined as PBC but without a positive antimitochondrial antibody. Primary sclerosing cholangitis was diagnosed on the basis of cholangiogram. RESULTS: Seventy-seven patients with possible autoimmune liver disease were identified. Of these, 42 had definite and seven probable AIH. At presentation, 34.7% of patients with AIH presented with acute icteric hepatitis, and 65.3% were asymptomatic. Persons presenting with mild or no symptoms were more likely to have moderate to severe fibrosis on liver biopsy than those presenting with jaundice. Eighteen persons were diagnosed with PBC, five with autoimmune cholangitis, five with overlap syndrome, and none with primary sclerosing cholangitis. The combined point prevalence of AIH Alaska natives was 42.9/100,000 (95% CI = 31-57.7). The prevalence of PBC was 16/100,000 (95% CI = 12.9-25.4). CONCLUSIONS: This population-based study demonstrates that the prevalence rates of AIH and PBC in Alaska natives are comparable with reported rates in other populations.


Subject(s)
Autoimmune Diseases/epidemiology , Ethnicity , Liver Diseases/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Alaska/ethnology , Female , Humans , Male , Middle Aged , Prevalence , Severity of Illness Index , Sex Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...